Chapter 12

This is a listing of all citations in this chapter.

91

Daszak/Callahan paper: “Diversity of coronavirus in bats from Eastern Thailand,” Virol J. 12 (2015): 57, doi: 10.1186/s12985-015-0289-1.

92

“Engineering Bio-Terror Agents: Lessons from the Offensive U.S. and Russian Biological Weapons Program,” House of Representatives, Subcommittee on Prevention of Nuclear and Biological Attack, Committee on Homeland Security (Jul. 13, 2005).

93

Matt Windsor, “The War on Bugs, Michael Callahan: Alumni Profile,” University of Alabama Medicine Magazine (Winter, 2013).

94

Richard Conniff, “How devastating pandemics change us,” National Geographic (Jul. 14, 2020).

95

Steve Watson, “Anthrax Coverup: A Government Insider Speaks Out,” 911 Blogger (2002).

96

Scott Lilly, “Getting Rich on Uncle Sucker: Should the Federal Government Strengthen Efforts to Fight Profiteering?” Center for American Progress (Oct. 2010).

97

Laura Rozen, “The anthrax vaccine scandal: Why did the Pentagon allow BioPort Corp. to remain the sole U.S. supplier of a crucial weapon against bioterror, despite years of failure to deliver the vaccine?” Salon (Oct. 15, 2001).

98

“Can Bioshield Effectively Procure Medical Countermeasures That Safeguard the Nation?” House of Representatives, Subcommittee on Emerging Threats, Cybersecurity and Science and Technology of the Committee on Homeland Security (Apr. 18, 2007), 49.

99

Sandra Sobieraj, “White House mail sorters anthrax-free,” Associated Press (Oct. 24, 2001).

100

Chris Hamby and Sheryl Gay Stolberg, “How One Firm Put an ‘Extraordinary Burden’ on the U.S.’s Troubled Stockpile,” The New York Times (Mar. 6, 2021).

101

Val Brickates Kennedy “VaxGen Wins Anthrax Vaccine Contract,” MarketWatch, Nov. 4, 2004.

102

Robert Roos, “HHS Cancels VaxGen Anthrax Vaccine Contract,” CIDRAP, Dec. 20, 2006.

103

Robert Roos, “VaxGen Sells Anthrax Vaccine to Rival Firm,” CIDRAP, May 7, 2008.

104

Chris Hamby and Sheryl Gay Stolberg, “How One Firm Put an ‘Extraordinary Burden’ on the U.S.’s Troubled Stockpile,” The New York Times (Mar. 6, 2021).

105

“HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax,” Emergent Biosolutions (Jul. 14, 2010).

106

“Emergent BioSolutions Awarded Contract to Develop a Dry Formulation of NuThrax, a Next Generation Anthrax Vaccine,” Business Wire (Sept. 8, 2014).

107

Chris Hamby and Sheryl Gay Stolberg, “How One Firm Put an ‘Extraordinary Burden’ on the U.S.’s Troubled Stockpile,” The New York Times (Mar. 6, 2021).

108

Chris Hamby and Sheryl Gay Stolberg, “How One Firm Put an ‘Extraordinary Burden’ on the U.S.’s Troubled Stockpile,” The New York Times (Mar. 6, 2021).

109

Chris Hamby and Sheryl Gay Stolberg, “How One Firm Put an ‘Extraordinary Burden’ on the U.S.’s Troubled Stockpile,” The New York Times (Mar. 6, 2021).

110

Whitney Webb and Raul Diego, “Head of the Hydra—The Rise of Robert Kadlec,” The Last American Vagabond (May 14, 2020).

111

Alex Knapp, “Little-Known Publicly Traded Company Given Massive Deal to Manufacture One-Shot Covid-19 Vaccine,” Forbes (Mar. 1, 2021).

112

“Emergent Buys Sanofi Pasteur’s Smallpox Vaccine for Up-to-$125M,” Gen Eng News (Jul. 14, 2017).

113

Whitney Webb and Raul Diego, “Head of the Hydra—The Rise of Robert Kadlec,” The Last American Vagabond (May 14, 2020).

114

“Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile,” Emergent Biosolutions (Sept. 3, 2019).

115

Jon Swaine, Robert O’Harrow Jr., and Aaron Davis, “Before pandemic, Trump’s stockpile chief put focus on biodefense. An old client benefited,” Washington Post (May 4, 2020).

116

Zhiyuan Sun, “Is There Any Hope Left for Emergent BioSolutions?” Motley Fool (Apr. 27, 2021).

117

Chris Hamby and Sheryl Gay Stolberg, “How One Firm Put an ‘Extraordinary Burden’ on the U.S.’s Troubled Stockpile,” The New York Times (Mar. 6, 2021).

118

Alex Knapp, “Little-Known Publicly Traded Company Given Massive Deal to Manufacture One-Shot Covid-19 Vaccine,” Forbes (Mar. 1, 2021).

119

Reuters Staff, “U.S. awards new $628 million contract to boost output of potential COVID-19 vaccine,” Reuters (Jun. 1, 2020).

120

“Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate,” Emergent BioSolutions (Jul. 27, 2020).